Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
Bipolar Androgen Therapy + Carboplatin in mCRPC (HiTeCH)

The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).

orchiectomy
androgen therapy
adenocarcinoma of prostate
serum testosterone
gonadotropin
  • 28 views
  • 12 Feb, 2022
  • 1 location
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone …

metastatic prostate cancer
measurable disease
orchiectomy
pet/ct
flutamide
  • 1807 views
  • 21 Mar, 2022
  • 468 locations
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line …

platelet count
breast adenocarcinoma
metastasis
taxane
trastuzumab
  • 5 views
  • 28 Feb, 2022
  • 3 locations
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC.

  • 0 views
  • 21 Apr, 2022
  • 1 location
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.

orchiectomy
adenocarcinoma of prostate
metastasis
medical castration
androgen suppression
  • 1 views
  • 30 Sep, 2021
  • 1 location
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS)

The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence …

  • 0 views
  • 05 Jun, 2022
  • 2 locations
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

In North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients. This phase III clinical trial is designed to compare the safety of a standard pelvic external beam …

ct scan
finasteride
prostate specific antigen
adenocarcinoma of prostate
hormone therapy
  • 224 views
  • 27 Sep, 2021
  • 13 locations
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

In ER+ and HER2- breast cancer(BC) patients for whom BCS is not feasible, we investigate the rate of BCS can be increased while decreasing unnecessary chemotherapy thru selective neoadjuvant chemotherapy or neoadjuvant endocrine therapy using tools of nodal status, Ki-67, and multigene assay(Mammaprint)

mammogram
erbb2
hormone therapy
metastasis
breast-conserving surgery
  • 0 views
  • 25 Feb, 2022
  • 1 location
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy

The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after

luteinizing hormone-releasing hormone agonist
PTEN
gonadorelin
  • 12 views
  • 23 Feb, 2022
  • 8 locations
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients

To assess the role of myocardial oedema on CMR (T2 mapping) after radiation therapy and cardiotoxic systemic therapy in predicting the incidence of cardiotoxicity, defined as by consensus guidelines* (decline of LVEF 10% points with a final LVEF <53%) measured on CMR and ECHO over the time window of 12 …

  • 0 views
  • 17 Mar, 2021
  • 1 location